Search Results

Bioartificial liver system approved for clinical trials in China.

• Authors : Shah AM

Subjects: End Stage Liver Disease* ; Liver, Artificial*; Humans

• Source: Artificial organs [Artif Organs] 2024 Mar; Vol. 48 (3), pp. 208-209. Date of Electronic Publication: 2023 Dec 16.Publisher: Wiley-Blackwell Country of Publication: United States NLM ID: 7802778 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Revealed: two men in China were first to receive pioneering stem-cell treatment for heart disease.

• Authors : Mallapaty S

Subjects: Cellular Reprogramming*; Heart Diseases/Heart Diseases/Heart Diseases/*therapy ; Induced Pluripotent Stem Cells/Induced Pluripotent Stem Cells/Induced Pluripotent Stem Cells/*transplantation

• Source: Nature [Nature] 2020 May; Vol. 581 (7808), pp. 249-250.Publisher: Nature Publishing Group Country of Publication: England NLM ID: 0410462 Publication Model: Print Cited Medium: Internet ISSN:

Record details

TO CHINA FOR A CURE.

• Authors : Shimo, Alexandra

Subjects: *MEDICAL care; STEM cells; THERAPEUTICSCHINA

• Source: Maclean's. 3/16/2009, Vol. 122 Issue 9, p40-41. 2p.

Record details

Frozen human brain tissue revived without damage.

• Authors : Lesté-Lasserre, Christa

• Source: New Scientist. 2024, Vol. 262, Issue 3492, pages. 14

Record details

Profile of Prof. Weizhi Ji.

Subjects: Disease Models, Animal*; Developmental Biology/Developmental Biology/Developmental Biology/*history ; Primate Diseases/Primate Diseases/Primate Diseases/*therapyJi W

• Source: Science China. Life sciences [Sci China Life Sci] 2019 Jan; Vol. 62 (1), pp. 8-11.Publisher: Science China Press, co-published with Springer Country of Publication: China NLM ID:

Record details

Takeda Highlights China NMPA Approval of LIVTENCITY (maribavir) for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies.

• Source: Entertainment Close-up. 2024.

Record details

Takeda Updates on China NMPA Approval of LIVTENCITY (maribavir) for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies.

• Source: Professional Services Close-Up. 2024.

Record details

Takeda Reports China NMPA Approval of LIVTENCITY (maribavir) for the Treatment of Adults with Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies.

• Source: Health & Beauty Close-Up. 2024.

Record details

A World of Approaches to Stem Cells.

Subjects: *LAW; EMBRYONIC stem cells; STEM cellsUNITED States; BRAZIL; UNITED Kingdom

• Source: Scientific American. Jul2005, Vol. 293 Issue 1, pA20-A21. 2p. 10 Color Photographs, 1 Map.

Record details

West China Second University Hospital Researchers Describe Findings in Cell Transplants (Cost analysis of childhood hematopoietic stem cell transplantation in Sichuan, China).

• Source: Women's Health Weekly. 2023, pages. 1172

Record details